ZINC CATION

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Zn
Molecular Weight	65.3956
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	2

SHOW SMILES / InChI

Structure Search

SMILES

[ZnH2+2]

InChI

InChIKey=PTFCDOFLOPIGGS-UHFFFAOYSA-N

InChI=1S/Zn/q+2

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459http://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6309044

Diammonium Zinc Disulfate is commonly used in fluid fertilizers. It is effective if properly applied in the soil (band application) and is less costly than chelate forms of zinc.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Streptococcus mutans 40 Target ID: CHEMBL612426 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 \| https://www.ncbi.nlm.nih.gov/pubmed/2913640	Inhibitor 7687
respiratory burst 38 Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083	Activator 1329
transformed cell apoptotic process 103 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Activator 1329
Methotrexate 37 Target ID: CHEMBL2364710 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Hydrolytic Enzyme 37
Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194	Interacts 314
T cell mediated immunity 39 Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Activator 1329
Zinc transporter ZIP1 37 Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 989
Zinc transporter ZIP2 37 Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 989

Conditions

Condition	Modality	Highest Phase	Product
Unknown
Unknown
Unknown
Caries 42 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 https://www.ncbi.nlm.nih.gov/pubmed/2913640 https://www.ncbi.nlm.nih.gov/pubmed/6353570	Preventing	Basic research	Unknown Approved Use Unknown
Ulcerative colitis 117 Sources: https://www.drugs.com/international/corticotropin-zinc-hydroxide.html https://www.ncbi.nlm.nih.gov/pubmed/13469787	Primary	Approved 7968	CORTROPHIN-ZINC Approved Use Treatment of ulcerative colitis and other colonic disorders. Launch Date -4.55328006E11
Zinc deficiency 38 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6383773	Primary	Preclinical	Unknown Approved Use Unknown
Acute myeloid leukemia 128 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Primary	Basic research	Unknown Approved Use Unknown
Breast cancer 411 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305766	Primary	Basic research	Unknown Approved Use Unknown
Renal insufficiency 39 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Secondary	Approved 7968	VORAXAZE Approved Use Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date 1.32675836E12
Diaper dermatitis 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021026s000lbl.pdf	Primary	Approved 7968	VUSION Approved Use INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. Launch Date 1.140048E12
Poison Ivy dermatitis 37 Sources: https://www.drugs.com/cdi/zinc-oxide-cream.html	Primary	Approved 7968	ZINC OXIDE Approved Use Unknown
Gastrointestinal disorders 91 Sources: https://www.drugs.com/pro/zinc-sulfate-injection.html	Primary	Approved 7968	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Mucositis 38 Sources: https://clinicaltrials.gov/ct2/show/NCT01015183	Primary	Phase III 650	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Dysgeusia 37 Sources: https://clinicaltrials.gov/ct2/show/NCT00036881	Primary	Phase III 650	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Unknown

PubMed

Title	Date	PubMed
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.	1991 Apr 1	9996367
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.	1993 Aug	8404763
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.	1994 Dec	7899834
Iron chelators as therapeutic agents against Pneumocystis carinii.	1994 May	8067783
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.	1995 Nov 13	7488149
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.	1997 Feb	9021177
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.	1997 May 16	11671728
Thujaplicin-copper chelates inhibit replication of human influenza viruses.	1998 Aug	9806486
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.	1999 Spring	10686872
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.	2002 Mar 1	11877378
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.	2004	16145958
Thermotoga maritima-Escherichia coli chimeric topoisomerases. Answers about involvement of the carboxyl-terminal domain in DNA topoisomerase I-mediated catalysis.	2004 Jul 16	15140883
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.	2004 Jul 16	15131129
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.	2004 Jul 30	15161915
High-throughput computational and experimental techniques in structural genomics.	2004 Oct	15489337
Impact of the mother's zinc deficiency on the woman's and newborn's health status.	2005	16240669
Erythrocyte zinc content in critically ill patients.	2005	16176172
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.	2005 Apr 27	15857667
Zinc in attention-deficit/hyperactivity disorder.	2005 Aug	16190793
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.	2005 Aug	16042674
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise.	2005 May	15883427
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.	2005 Nov-Dec	16277018
Characterization and inhibition of SARS-coronavirus main protease.	2006	16611148
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.	2006 Nov 10	17081022
Zinc homeostasis in aging: two elusive faces of the same "metal".	2006 Summer	16706668
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.	2007 Nov	18055849
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.	2009 Mar 28	19382294
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.	2010 Dec	21119035
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.	2010 Dec 15	20934491
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.	2010 Feb	19755143
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.	2010 Jan 12	19897006
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.	2010 Jul	20194077
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.	2011 Dec	21903158
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.	2011 Jul	21481475
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.	2011 Jun	19833686
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?	2011 Mar 1	21220601
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.	2011 Mar 21	21341804
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.	2011 Sep	21642632
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.	2012 Mar	22166487
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.	2013 Dec	24060544
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.	2013 Jan	22083529
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.	2013 Mar	23232460
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.	2013 Sep	23352990
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.	2014 Jan	23832296
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.	2014 Jul 1	24746987
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.	2014 Nov 4	25127755
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.	2015 Apr 2	25680694
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.	2015 Jan 25	25173522
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.	2015 Sep	25940351
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.	2016 Sep	26892107

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Name

Type

Language

ZINC CATION

Common Name

English

ZINC ION

Common Name

English

ZINC(II)

Systematic Name

English

ZINC ION(2+)

Common Name

English

ZINC(2+)

Systematic Name

English

ZINC, ION (ZN2+)

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175530